LexaGene granted management cease trade order

2022 06 21 20 59 0869 Business Agreement 400

Molecular diagnostics firm LexaGene said Thursday that it has been granted a management cease trade order imposed against certain insiders of the company, preventing them from trading the firm’s securities.

The company said that the order, issued under Canadian national policy, will be in effect until its annual financial statements for the year ended February 28, management's discussion and analysis, and CEO and CFO certifications are filed on or before August 29.

LexaGene had announced on Tuesday that its annual Canadian financial filings would not be filed with Canadian Securities Administrators by the required deadline of June 28.

The firm said Thursday that it expects to file the required documents within the next five to six weeks.

Page 1 of 138
Next Page